Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Significant Decrease in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 223,898 shares, a drop of 73.3% from the July 30th total of 839,994 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average daily volume of 903,947 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On Matinas Biopharma

A hedge fund recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent quarter. Hedge funds and other institutional investors own 11.77% of the company’s stock.

Matinas Biopharma Stock Performance

Shares of Matinas Biopharma stock traded up $0.00 during trading on Thursday, reaching $0.20. The company’s stock had a trading volume of 810,866 shares, compared to its average volume of 2,159,492. Matinas Biopharma has a one year low of $0.18 and a one year high of $2.14. The firm has a market cap of $2.94 million, a price-to-earnings ratio of -0.17 and a beta of 1.76. The business’s fifty day moving average price is $0.40 and its 200-day moving average price is $0.55.

Matinas Biopharma (NYSEAMERICAN:MTNB) last announced its earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical?stage biopharmaceutical company that specializes in the development of novel lipid?based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water?soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life?threatening fungal infections.